

#### UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Program Number	2023 P 1334-4
Program	Prior Authorization/Notification
Medication	Lampit <sup>®</sup> (nifurtimox)
P&T Approval Date	11/2020; 11/2021, 11/2022, 11/2023
Effective Date	2/1/2024

#### 1. Background:

Lampit is a nitrofuran antiprotozoal indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by *Trypanosoma cruzi*.

Antiparasitic treatment is indicated for all cases of acute or reactivated Chagas disease and for chronic *Trypanosoma cruzi (T. cruzi)* infection in children up to 18 years old. Congenital infections are considered acute disease. Treatment is strongly recommended for adults up to 50 years old with chronic infection who do not already have advanced Chagas cardiomyopathy. For adults older than 50 years with chronic *T. cruzi* infection, the decision to treat with antiparasitic drugs should be individualized, weighing the potential benefits and risks for the patient. Physicians should consider factors such as the patient's age, clinical status, preference, and overall health.<sup>2</sup>

# 2. Coverage Criteria<sup>a</sup>:

# A. <u>Authorization</u>

- 1. Lampit will be approved based on the following criterion:
  - a. Diagnosis of Chagas disease (American trypanosomiasis) caused by *Trypanosoma cruzi*

#### Authorization will be issued for 60 days.

<sup>a</sup> State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

# 3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.



### 4. References:

- 1. Lampit [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; June 2023.
- 2. CDC Guidelines. Parasites American Trypanosomiasis (also known as Chagas Disease). https://www.cdc.gov/parasites/chagas/. Accessed September 2023.

Program	Prior Authorization/Notification – Lampit (nifurtimox)
Change Control	
11/2020	New program.
11/2021	Annual review. Updated references.
11/2022	Annual review. Added state mandate language. Updated references.
11/2023	Annual review. Updated references.